Foslevodopa/Foscarbidopa

The TEMPO-1 and TEMPO-2 trials demonstrated that tavapadon, a selective D1/D5 dopamine receptor agonist, significantly improved motor function in newly diagnosed Parkinson's disease patients compared to placebo.

AbbVie's Emblaveo, a groundbreaking aztreonam-avibactam combination, receives FDA approval for treating complicated intra-abdominal infections with limited treatment options.

AbbVie's Vyalev, a 24-hour subcutaneous levodopa infusion, gained FDA approval for managing motor fluctuations in advanced Parkinson's, offering a novel therapeutic approach.

Vyalev, a new subcutaneous drug therapy by AbbVie for Parkinson's disease, has been approved by the FDA in October 2024 after successful Phase 3 trials.

AbbVie has completed its acquisition of Aliada Therapeutics for $1.4 billion, gaining access to ALIA-1758, a Phase 1 Alzheimer's treatment.